Subsequently, For the treatment of individuals with locally advanced or metastatic NSCLC that has the KRAS G12C mutation, the FDA authorized sotorasib in 2021 (Punekar et al., 2022). This evidence concerns the gene KRAS and non-small cell lung carcinoma.